


Supplementary Figure S1.



Supplementary Figure S1. Cell viability in normoxic conditions with or without varying rosiglitazone concentrations. Results are presented as mean with standard error. **(a): Adult rat cardiomyocytes.** Normoxia (N) + vehicle group was set to 100% relative fluorescent units (RFU), and all of the data were normalized to the averaged N + vehicle group. Rosiglitazone treatment did not aggravate cell death in normoxic conditions in adult rat cardiomyocytes. (Kruskal–Wallis, Dunn’s post hoc, * $p < 0.05$ vs. N + vehicle, $n=7-9$, 25-66 technical replicates) **(b): AC16 cell line.** Normoxia (N) + vehicle group was set to 100% RFU, and all of the data were normalized to the averaged medium treated group. Rosiglitazone treatment aggravated cell death in normoxic conditions in AC16 cells with 10 μ M. (Kruskal–Wallis, Dunn’s post hoc, * $p < 0.05$ vs. N + vehicle, $n=6-7$, 69-108 technical replicates) **(c): Differentiated AC16 cell line.** Normoxia (N) + vehicle group was set to 100% RFU, and all of the data were normalized to the averaged medium treated group. Rosiglitazone treatment did not aggravate cell death in normoxic conditions in differentiated AC16 cells. (Kruskal–Wallis, Dunn’s post hoc, * $p < 0.05$ vs. N + vehicle, $n=5$, 31-73 technical replicates)

N: normoxia. **veh:** vehicle. **rosi:** rosiglitazone. **RFU:** relative fluorescence unit.

Supplementary Table S1.

Body-weight-development of rats under chronic rosiglitazone treatment

	day-1	day0	day1	day2	day3	day4	day5	day6	day7	day8
Mean +/- SEM vehicle	96.1 ±2.3	102.5 ±1.9	111.1 ±2.0	118.9 ±2.1	125.9 ±2.2	134.9 ±2.3	143.0 ±2.4	150.7 ±2.5	158.4 ±2.5	166.8 ±2.6
Mean +/- SEM rosiglitazone	94.7 ±2.3	103.2 ±1.7	110.7 ±1.8	118.5 ±1.9	125.9 ±2.0	133.9 ±2.0	141.5 ±2.2	148.1 ±2.1	156.1 ±2.2	163.4 ±2.3
	day9	day10	day11	day12	day13	day14	day15	day16	day17	day18
Mean +/- SEM vehicle	174.3 ±2.7	180.3 ±3.5	190.1 ±3.0	197.0 ±3.0	204.1 ±3.0	211.5 ±3.2	221.8 ±4.0	226.5 ±3.4	234.1 ±3.5	242.4 ±3.6
Mean +/- SEM rosiglitazone	170.5 ±2.4	177.5 ±2.4	185.5 ±2.7	192.1 ±2.7	198.6 ±2.8	204.8 ±2.8	212.3 ±2.8	219.2 ±3.0	225.9 ±2.9	234.3 ±3.0
	day19	day20	day21	day22	day23	day24	day25	day26	day27	day28
Mean +/- SEM vehicle	249.7 ±3.6	257.0 ±3.7	263.7 ±4.0	272.3 ±3.8	277.9 ±4.1	284.3 ±4.3	290.6 ±4.5	293.7 ±5.4	302.6 ±4.8	307.8 ±4.8
Mean +/- SEM rosiglitazone	241.4 ±3.1	245.0 ±3.8	254.2 ±3.2	261.3 ±3.3	267.9 ±3.4	271.5 ±3.7	278.7 ±3.4	282.4 ±4.5	288.9 ±3.8	295.6 ±3.8

Supplementary Table S1. Weight development of male Wistar rats under chronic rosiglitazone treatment vs. vehicle. Results are presented as mean ± SEM. During the 28-day treatment, the weight gain did not change with rosiglitazone treatment compared to the vehicle group (1% hydroxyethyl-cellulose).(Mixed effect analysis, Sidak’s post hoc, day -1: n=25, day 0-28: n=40)

Supplementary Table S2.

Heart rate measurement during surgical protocol in rats

surgical period	start	ischemia				reperfusion			
time	0 min	45 min	60 min	75 min	100 min	130 min	160 min	190 min	
Mean +/- SEM I/R vehicle	452 ±15	429 ±19	386 ±41	416 ±17	412 ±19	430* ±16	431 ±21	417 ±22	
Mean +/- SEM I/R rosiglitazone	427 ±11	436 ±23	426 ±20	426* ±12	425 ±15	402 ±11	396 ±18	410 ±17	
Mean +/- SEM IPC vehicle	425 ±18	422 ±18	387 ±14	395 ±16	401 ±14	396 ±14	404 ±14	404 ±18	
Mean +/- SEM IPC rosiglitazone	427 ±30	397 ±13	390 ±21	375 ±13	378 ±15	368 ±15	369 ±15	367 ±16	

Supplementary Table S2. Mean heart rate was monitored throughout the entire in vivo surgery protocol. Results are presented as mean ± SEM. There is no meaningful difference between the treatment groups with respect to the heart rate. (Mixed effect analysis, Tukey’s post hoc, * $p < 0.05$ vs. IPC rosiglitazone, n=9-13)

Supplementary Table S3.

Blood pressure measurement during surgical protocol in rats

Surgical period	start	ischemia				reperfusion		
time	0 min	45 min	60 min	75 min	100 min	130 min	160 min	190 min
Mean +/- SEM I/R vehicle	96,3 ±9	81,1 ±6,2	60,9 ±7	78,1 ±6,9	75,3 ±4,1	78,8 ±4,7	75,4 ±5,4	76,5 ±4,5
Mean +/- SEM I/R rosiglitazone	102,2 ±8,9	63,2 ±8,6	76 ±8,2	85,3 ±12,7	85,4 ±6,7	83,2 ±7,1	91,7 ±8,5	86,7 ±6,8
Mean +/- SEM IPC vehicle	96,2 ±7	74,5 ±5,3	62,7 ±6,6	89,6 ±3,9	84,2 ±4,8	80,6 ±5,4	79,9 ±3	80,5 ±5,8
Mean +/- SEM IPC rosiglitazone	93,8 ±4,7	75,2 ±5,1	68 ±6,1	78,3 ±6,1	80,3 ±5,3	74 ±5,6	77,2 ±4,4	75,4 ±5,6

Supplementary Table S3. Mean arterial blood pressure was monitored throughout the entire in vivo surgery protocol. Results are presented as mean ± SEM. There is no significant difference between the treatment groups with respect to the blood pressure. (Mixed effect analysis, Tukey’s post hoc, n=9-13)